Variables determining mortality in patients with Acinetobacter baumannii meningitis/ventriculitis treated with intrathecal colistin

Simple item page
dc.contributor.authorCeylan B.
dc.contributor.authorArslan F.
dc.contributor.authorSipahi O.R.
dc.contributor.authorSunbul M.
dc.contributor.authorOrmen B.
dc.contributor.authorHakyemez İ.N.
dc.contributor.authorTurunc T.
dc.contributor.authorYıldız Y.
dc.contributor.authorKarsen H.
dc.contributor.authorKaragoz G.
dc.contributor.authorTekin R.
dc.contributor.authorHizarci B.
dc.contributor.authorTurhan V.
dc.contributor.authorSenol S.
dc.contributor.authorOztoprak N.
dc.contributor.authorYılmaz M.
dc.contributor.authorOzdemir K.
dc.contributor.authorMermer S.
dc.contributor.authorKokoglu O.F.
dc.contributor.authorMert A.
dc.date.accessioned2024-07-22T08:10:57Z
dc.date.available2024-07-22T08:10:57Z
dc.date.issued2017
dc.description.abstractAim To examine the variables associated with mortality in patients with Acinetobacter baumannii-related central nervous system infections treated with intrathecal colistin. Materials and methods This multi-centre retrospective case control study included patients from 11 centres in Turkey, as well as cases found during a literature review. Only patients with CNS infections caused by multidrug-resistant or extensively drug-resistant Acinetobacter baumannii treated with intrathecal colistin were included in this study. The variables associated with mortality were determined by dividing the patients into groups who died or survived during hospitalisation, and who died or survived from Acinetobacter meningitis. Results Among the 77 cases enrolled in the study, 35 were found through a literature review and 42 were cases from our centres. Forty-four cases (57.1%) were male and the median age was 48 years (range: 20–78 years). Thirty-seven patients (48%) died during hospitalisation. The variables associated with increased all-cause mortality during hospitalisation included old age (odds ratio, 1.035; 95% confidence interval (CI), 1.004–1.067; p = 0.026) and failure to provide cerebrospinal fluid sterilisation (odds ratio, 0.264; 95% confidence interval, 0.097–0.724; p = 0.01). There is a trend (P = 0.062) towards higher mortality with using of meropenem during meningitis treatment. Fifteen cases (19%) died from meningitis. There were no significant predictors of meningitis-related mortality. Conclusions The mortality rate for central nervous system infections caused by multidrug-resistant or extensively drug-resistant Acinetobacter baumannii is high. Old age and failure to provide CSF sterilisation are associated with increased mortality during hospitalisation. © 2016
dc.identifier.DOI-ID10.1016/j.clineuro.2016.12.006
dc.identifier.issn03038467
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15461
dc.language.isoEnglish
dc.publisherElsevier B.V.
dc.subjectAcinetobacter baumannii
dc.subjectAcinetobacter Infections
dc.subjectAdult
dc.subjectAged
dc.subjectAnti-Bacterial Agents
dc.subjectCase-Control Studies
dc.subjectCerebral Ventriculitis
dc.subjectColistin
dc.subjectFemale
dc.subjectHumans
dc.subjectInjections, Spinal
dc.subjectMale
dc.subjectMeningitis, Bacterial
dc.subjectMiddle Aged
dc.subjectOutcome Assessment (Health Care)
dc.subjectRetrospective Studies
dc.subjectThienamycins
dc.subjectYoung Adult
dc.subjectamikacin
dc.subjectcefazolin
dc.subjectcefepime
dc.subjectceftazidime
dc.subjectceftriaxone
dc.subjectcefuroxime
dc.subjectciprofloxacin
dc.subjectcolistin
dc.subjectgentamicin
dc.subjectimipenem
dc.subjectlevofloxacin
dc.subjectlinezolid
dc.subjectmeropenem
dc.subjectpiperacillin plus tazobactam
dc.subjectrifampicin
dc.subjectsulbactam
dc.subjectteicoplanin
dc.subjecttigecycline
dc.subjectvancomycin
dc.subjectantiinfective agent
dc.subjectcolistin
dc.subjectmeropenem
dc.subjectthienamycin derivative
dc.subjectAcinetobacter infection
dc.subjectadult
dc.subjectaged
dc.subjectantibiotic therapy
dc.subjectArticle
dc.subjectbacterial meningitis
dc.subjectbrain ventriculitis
dc.subjectcase control study
dc.subjectcentral nervous system infection
dc.subjectcerebrospinal fluid
dc.subjectdisease association
dc.subjectfemale
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmiddle aged
dc.subjectmortality
dc.subjectmulticenter study
dc.subjectnonhuman
dc.subjectretrospective study
dc.subjectyoung adult
dc.subjectAcinetobacter baumannii
dc.subjectAcinetobacter Infections
dc.subjectCerebral Ventriculitis
dc.subjectclinical trial
dc.subjectintraspinal drug administration
dc.subjectMeningitis, Bacterial
dc.subjectmortality
dc.subjectoutcome assessment
dc.subjectpathogenicity
dc.titleVariables determining mortality in patients with Acinetobacter baumannii meningitis/ventriculitis treated with intrathecal colistin
dc.typeArticle

Files

Collections

Scopus Koleksiyonu